An open label multicentric study to assess the efficacy and safety of Atorvastatin + Ramipril + Aspirin + Metoprolol (as extended release) fixed dose combination capsules for secondary prophylaxis in patients with ischemic heart disease.

Trial Profile

An open label multicentric study to assess the efficacy and safety of Atorvastatin + Ramipril + Aspirin + Metoprolol (as extended release) fixed dose combination capsules for secondary prophylaxis in patients with ischemic heart disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Atorvastatin/aspirin/metoprolol/ramipril (Primary)
  • Indications Ischaemic heart disorders
  • Focus Therapeutic Use
  • Sponsors Cadila Healthcare
  • Most Recent Events

    • 20 Mar 2010 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India.
    • 13 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top